Watson enter permit deal to commercialize Anturol in the U.

Antares, Watson enter permit deal to commercialize Anturol in the U.S cliquer ici . And Canada Watson Pharmaceuticals, Inc. and Antares Pharma, Inc. today announced a special licensing contract for Watson to commercialize Antares’ topical oxybutynin gel product in the U.S. And Canada. A New Drug Software for the oxybutynin gel product happens to be under review by the Food and Medication Administration . The FDA has designated a Prescription Drug Consumer Fee Act time of December 8, 2011. Upon launch of the product, Antares shall receive escalating royalties predicated on revenue in the U.S. And Canada. Additional information on the agreement have not really been disclosed. Antares’ oxybutynin product is a clear, odorless topical gel that has demonstrated to become an effective and safe treatment for overactive bladder , a condition that impacts a lot more than 30 million Americans.

Other entries from category "rheumatology":

Random entries